Amgen (AMGN) Offering Possible 16.82% Return Over the Next 15 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $172.50 short put and a strike $167.50 long put offers a potential 16.82% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $172.50 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $4.28 would be incurred if the stock dropped below the $167.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 70.57 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Amgen

5 Clinical-Stage Biotech Stocks to Buy Under $10
Tue, 29 May 2018 14:24:22 +0000
After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. The key is in finding those smaller drug firms that have the ability to actually get through clinical trials and start marketing drugs. Likewise, spreading your money around to a variety of clinical stage names is also paramount if you want to play in the space.

Keytruda and Lynparza Are Expected to Be Merck’s Growth Drivers
Tue, 29 May 2018 13:01:42 +0000
The company generated revenues of $24 million and $9 million, respectively, from the sales of Lynparza in US and international markets. In May, the EMA (European Medicines Agency) approved Lynparza 300 mg tablets twice daily as a maintenance therapy for individuals with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who showed a complete or partial response to platinum-containing chemotherapy irrespective of BRCA designation.

Insights into the Cash Flows and Valuations of Editas Medicine
Tue, 29 May 2018 12:15:27 +0000
Since the beginning of 2018, Editas Medicine’s (EDIT) share price has risen 5.1% to close at $36.06 on May 23. The stock touched a high of $46 on March 9 and a low of $43.1 on April 30.

The Upside Potential in Editas Medicine Stock
Tue, 29 May 2018 12:15:26 +0000
Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

How Clovis Oncology’s Cash Flow and Valuation Compare
Mon, 28 May 2018 19:02:08 +0000
In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising. Clovis’s investments fell YoY to $9.8 million from $86.6 million due to the company buying $133 million in available-for-sale securities and selling $50 million in securities in 2017. In the first quarter of this year, Clovis sold $10 million in available-for-sale securities and purchased $217,000 in property and equipment. Clovis generated $226.9 million from financing activities in the first quarter of 2017.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.